Microbial therapeutics: New opportunities for drug delivery
微生物疗法:药物递送的新机会
10.1084/jem.20190609
04-26, Editorial Material
Abstract & Authors:展开
Abstract:收起
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.
First Authors:
Miguel Jimenez
Correspondence Authors:
Robert Langer,Giovanni Traverso
All Authors:
Miguel Jimenez,Robert Langer,Giovanni Traverso
联系客服